The pharmaceutical industry and its pricing methods provide an inviting target, easy to disparage and caricature. Even after accounting for discounts and rebates, average prices of leading brand-name drugs in the US are two to four times higher than they are in Canada, Japan, and many European countries. US per capita spending on prescription drugs is more than twice the level in the United Kingdom. Prices for most new cancer drugs now exceed $100,000 per patient per year of treatment, despite the fact that many of these ...
Read More
The pharmaceutical industry and its pricing methods provide an inviting target, easy to disparage and caricature. Even after accounting for discounts and rebates, average prices of leading brand-name drugs in the US are two to four times higher than they are in Canada, Japan, and many European countries. US per capita spending on prescription drugs is more than twice the level in the United Kingdom. Prices for most new cancer drugs now exceed $100,000 per patient per year of treatment, despite the fact that many of these treatments seem to offer modest gains in life expectancy or lack such evidence at all. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million dollar price tags, the need for sensible drug pricing and coverage policies will intensify.
Read Less
Add this copy of The Right Price: A Value-Based Prescription for Drug to cart. $59.76, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2021 by Oxford University Press.
